To compare the circulating levels of adiponectin and nitric oxide (NO) bioavailability in eutrophic, eutrophic hypertensive, obese, and obese hypertensive children and adolescents, and to assess whether adiponectin is associated with increased NO bioavailability in these children and adolescents. METHODS: We studied 129 eutrophic, 8 eutrophic hypertensive, 91 obese, and 44 obese hypertensive children and adolescents in this cross-sectional study. Adiponectin concentrations were measured in plasma samples by enzyme-linked immunosorbent assay. To assess NO bioavailability, nitrite concentrations were measured in whole-blood samples by chemiluminescence. Multiple linear regression analysis was carried out to assess the effects of adiponectin on NO bioavailability. RESULTS: We found no significant differences in nitrite levels among groups (P40.05). The obese hypertensive group had the lowest adiponectin levels among groups (Po0.05). Additionally, obese subjects had lower adiponectin levels than eutrophic individuals (Po0.05). A multiple linear regression analysis showed that NO bioavailability was positively associated with adiponectin concentrations (Po0.05). CONCLUSIONS: Our findings suggest that adiponectin increases NO bioavailability in children and adolescents. Further studies are needed to assess the cardiovascular protective role for this adipokine in childhood obesity.
INTRODUCTION
The prevalence of obesity among children and adolescents has reached epidemic proportions worldwide. 1 This clinical condition is a risk factor for development of diabetes, dyslipidemia, hypertension and atherosclerotic diseases. 2 Indeed, adipose tissue in obese subjects is dysfunctional and releases a large number of bioactive mediators, such as inflammatory proteins, and many prothrombotic and atherogenic factors. 3 Adiponectin is abundantly expressed in adipose tissue, sensitizes the body to insulin, and has anti-inflammatory and anti-atherogenic properties. 4 It was initially recognized as an adipokine dysregulated in obesity 5 and plasma adiponectin relates inversely to adiposity in adults and children. 6, 7 Hypoadiponectinemia is also associated with atherosclerosis [8] [9] [10] and hypertension. 11, 12 The cardiovascular protective role of adiponectin may be attributed to its ability to inhibit smooth muscle cell proliferation, monocyte adhesion to endothelial cells and accumulation of lipids in the macrophages. 13, 14 Moreover, adiponectine was shown to stimulate the production of nitric oxide (NO) by vascular endothelial cells. 15 Nitric oxide is a major mediator that has an important role in vascular homeostasis, prevents platelet and leukocyte adhesion, and inhibits vascular smooth muscle cell migration and proliferation. 16 Reduced NO bioavailability has been linked to hypertensive disorders. 17 In childhood obesity, conflicting results were shown with respect to NO bioavailability, 18, 19 whereas some evidence supports the idea that increased NO formation would be associated with corresponding alterations in adiponectin levels. 15, 20, 21 Importantly, low plasma adiponectin levels have been associated with impaired endothelium-dependent dilatation in healthy subjects. 22 However, no previous study has examined the association between plasma adiponectin concentrations and markers of NO bioavailability in obese children.
Because alterations in adiponectin and NO levels may promote hypertension, 4, 16 and as obesity is the most common cause of hypertension in children, 23 the present study assessed (1) whether there are significant alterations in the plasma concentrations of adiponectin and nitrite (a relevant marker of NO bioavailability) 24 in eutrophic, eutrophic hypertensive, obese, and obese hypertensive children and adolescents, and (2) whether adiponectin levels are associated with NO bioavailability in these children and adolescents.
MATERIALS AND METHODS Subjects
Approval for use of human subjects in this cross-sectional study was obtained from the Institutional Review Board at the Federal University of Juiz de Fora, Brazil. Parents and children were informed as to the nature and purpose of the study. Parents gave their written consent and children gave their verbal consent.
The study population consisted of 129 eutrophic, 8 eutrophic hypertensive, 91 obese, and 44 obese hypertensive children and adolescents recruited from the Endocrinology Ambulatory of the Adolescent and Child Institute, from the Childhood Endocrinology Ambulatory of the IMEPEN Foundation and from the local community at Juiz de Fora.
All children underwent thorough physical examination. Height was measured to the nearest 0.1 cm by using a wall-mounted stadiometer. Body weight was measured with a digital scale to the nearest 0.1 kg. Body mass index was calculated as the weight in kilograms divided by height in meters squared. Obesity was defined as body mass index greater than the 95th percentile, and eutrophia between 10th and 84th percentiles, matched according to age and sex. 25 Systolic blood pressure and diastolic blood pressure were measured at least three times and the presence of hypertension was defined as systolic blood pressure and/or diastolic blood pressure exceeding the 95th percentile. 26 
Laboratory analyses
Glucose concentrations and lipid parameters (total cholesterol, triglycerides, high-density lipoprotein cholesterol) were determined in plasma and serum, respectively, with routine enzymatic methods using commercial kits (Labtest Diagnostic, SA, Lagoa Santa, Brazil). Low-density lipoprotein concentration was calculated according to the Friedewald formula.
Enzyme immunoassays of adiponectin and insulin
Venous blood samples were collected after overnight (8-12 h) fasting, immediately centrifuged at 2000 g for 10 min at room temperature, and plasma samples were stored at À 70 1C until analyzed. MMP-9, TIMP-1 and adiponectin concentrations were measured in EDTA-plasma using commercially available enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Insulin concentrations were measured in EDTA-plasma using a kit (Genese Produtos Diagnosticos, Sao Paulo, Brazil). The estimate of insulin resistance obtained by homeostasis model assessment index (HOMA IR) was calculated as previously described. 27 Measurement of nitrite concentrations in whole-blood samples
To measure whole-blood nitrite concentrations in triplicate, venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson, Sao Paulo, Brazil) containing heparin, and immediately mixed with a nitrite preservation solution in a 5:1 dilution as previously described. 28 Briefly, this solution contains 0.8 M ferricyanide and 1% NP-40. The samples were analyzed for their nitrite content using an ozone-based chemiluminescence assay, as previously described. 29 The samples were deproteinated with methanol (1:1) and centrifuged at 14 000 g for 5 min. Then 200 ml supernatant were injected into a solution of acidified triiodide, purging with in-line nitrogen with a gas-phase chemiluminescence NO analyzer (Sievers Model 280 NO Analyzer, Sievers, Boulder, CO, USA). 30 Approximately 8 ml of triiodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 ml of water with 140 ml of acetic acid) was placed in the purge vessel into which the samples were injected. Thitriiodide solution reduced nitrites to NO gas, which was detected by the NO analyzer.
Statistical analysis
All results are expressed as mean ± s.d. (Table 1) , or are shown as box plots and the median (Figures 1 and 2) . ANOVA was used to compare normally distributed variables. The Kruskall-Wallis test was used to compare nonnormally distributed variables. Multiple linear regression was performed to assess the relationship between nitrite concentrations and clinical variables that could influence their levels. Sex, age, waist-to-hip, hypertension, obesity and adiponectin were included as independent variables in a multiple linear regression model to explain changes in nitrite concentrations using SAS 9.0 software (SAS Institute Inc., Cary, NC, USA). The results were defined as statistically significant when Po0.05.
RESULTS
Demographic, anthropometric and biochemical characteristics are shown in Table 1 . The obese group had slightly lower ages when compared with other groups (Po0.05). The eutrophic/hyp group had a higher prevalence of boys than the other groups. As expected, significant differences were found among groups in terms of anthropometric measurements: body mass index and waist-to-hip ratio were higher in the obese groups versus the eutrophic groups (Po0.05). Additionally, arterial blood pressure was higher in obese/hyp, obese and eutrophic/hyp groups when compared with the eutrophic group (Po0.05). With regard to biochemical parameters, obese and obese/hyp groups had higher glycemia, HOMA, total cholesterol, low-density lipoprotein cholesterol and triglyceride levels than the eutrophic group (Po0.05). The obese and obese/hyp groups presented lower high-density lipoprotein cholesterol than the eutrophic group (Po0.05), and the obese/hyp group had higher triglyceride levels than the eutrophic/hyp group (Po0.05).
We found no significant differences in nitrite levels among groups (Figure 1; P40.05) . However, the obese/hyp group had the lowest adiponectin levels among groups (Po0.05), and the obese group had lower adiponectin levels than the eutrophic group (Po0.05).
To determine the influence of adiponectin concentrations and clinical variables (gender, age, waist-to-hip ratio, hypertension and obesity) on NO bioavailability, we performed a multiple linear regression analysis with all children enrolled in this study ( Table 2 ). The clinical variables mentioned above did not affect nitrite concentrations (P40.05). Finally, after adjustment for these selected variables, we found that nitrite concentrations were significantly and positively affected by adiponectin concentrations (Po0.05).
DISCUSSION
The main findings of the present study are that: (i) obese hypertensive children and adolescents had the lowest adiponectin levels, and (ii) NO bioavailability was positively affected by adiponectin concentrations, although we found no significant differences in nitrite levels among groups.
Adiponectin, a hormone produced and secreted by adipocytes, is found at relatively high concentrations in the circulation, thus suggesting that it has an important physiological role. Indeed, this adipokine sensitizes the body to insulin and has an important role in the metabolism of glucose and lipids. Moreover, it has antiinflammatory and anti-atherogenic properties, and has emerged as an important mediator modifying the cardiovascular risk. 4, [9] [10] [11] 13 In the present study, we found that obese children and adolescents had lower plasma adiponectin than non-obese, and these results are consistent with previous data showing lower adiponectin levels in obese children and adolescents. 7, [31] [32] [33] Interestingly, our results showed that obese hypertensive children have the lowest plasma adiponectin levels, thus suggesting that these children are exposed at increased cardiovascular risk. This particular finding is in line with previous studies showing that hypoadiponectinemia is associated with hypertension in adults. 11, 12 In addition, a recent study reported that adiponectin levels were negatively associated with systolic blood pressure in male children. 34 The positive association that we found between NO bioavailability and adiponectin concentrations supports the suggestion that adiponectin may exert protective effects with respect to the cardiovascular system, as a result of increased NO formation in proportion with the adiponectin levels. Indeed, studies have shown that adiponectin may promote NO formation by affecting eNOS expression and eNOS phosphorylation, thus enhancing enzyme activity. eNOS upregulation could explain some of the beneficial effects exerted on endothelial and vascular smooth muscle cell function. 15, 21, 22 Notwithstanding the fact that we found significant differences in the adiponectin levels among groups, and that NO bioavailability was positively affected by adiponectin concentrations, we did not find significant differences in nitrite levels among groups. Together, these findings suggest that other factors (in addition to adiponectin) may influence NO bioavailability. In obese juveniles, lower nitrate/nitrite (usually termed NOx) levels were found in comparison with non-obese juveniles. 18 However, increased NOx concentrations were also found in obese children and this finding has been related to the metabolic syndrome. 19, 35 Importantly, nitrite has been suggested as a relevant marker of endogenous NO formation, and inhibition of NO formation decreased circulating nitrite levels by 80%. 36 It is now clear that NOx is a much less reliable marker of endogenous NO bioavailability than nitrite levels, which are considered relevant markers of NO bioavailability, 37, 38 and these levels correlate with cardiovascular risk factors. 38, 39 However, we found no major differences in nitrite concentrations when eutrophic hypertensive children were compared with eutrophic normotensive children. This finding may be limited by the small number of eutrophic hypertensive subjects enrolled in the present study.
We carried out a multiple linear regression to assess the relationship between nitrite concentrations and clinical variables that could influence nitrite levels, and obesity and hypertension did not affect nitrite concentrations. Obesity is the most common cause of hypertension in children and adolescents, and conflicting results exist with respect to the levels of NO metabolites in obesity, especially in children and adolescents. It is usually accepted that obesity is associated with a compensatory increase in NO synthesis at the initial stage of obesity, which is followed by a decline. 1, 2 Clinical studies showed significant increases rather than reductions in NO levels in obese children, particularly in the presence of a cluster of metabolic risk factors, including hypertension. 3, 4 On the other hand, Gruber et al. 40 found lower NO levels in obese adolescents. 5 Therefore, changes in NO production could affect the circulating levels of NO markers during the development of obesity, and further studies are needed to explore how metabolic syndrome parameters such as hypertension affect NO bioavailability in children and adolescents.
In conclusion, we found evidence indicating that adiponectin could promote NO bioavailability in children and adolescents, thus suggesting a cardiovascular protective role for this adipokine in , proportion of the variation in the response around the mean that can be attributed to terms in the model rather than to random error; r.m.s.e., root mean square error; WHR, waistto-hip; y, yes for hypertension or obesity. *Statistically significant (Po0.05). childhood obesity. Hence, adiponectin pathway may be a useful therapeutic target against cardiovascular complications in obesity.
